Siemens Healthineers Management
As the company's top management body, the Managing Board is committed to serving the interests of the company and achieving sustainable growth in company value.
The members of the Managing Board are jointly responsible for the entire management of the company and decide on the basic issues of business policy and corporate strategy.
Dr. Bernd Montag
Bernd Montag, Ph.D., has been CEO of Siemens Healthineers since February 2015. As of March 2018, the company is listed on the Frankfurt Stock Exchange as Siemens Healthineers AG (SHL). In June 2018 it entered the technology index TecDAX.
Bernd Montag joined Siemens in 1995, after completion of his studies in Physics at the Friedrich-Alexander-University, Erlangen-Nuremberg, and earning a Ph.D. in theoretical multi-particle physics. He held positions in corporate quality management and sales in the hearing aid division before moving to imaging systems in 1999, where he served as a product manager for computed tomography and as the head of marketing for magnetic resonance business. In 2004, he assumed overall responsibility for computed tomography, and in 2008, he was named President of the Imaging & Therapy Division, which combined the overall business of diagnostic imaging and image-guided therapies.
Dr. Jochen Schmitz
Jochen Schmitz, Ph.D., has been Chief Financial Officer (CFO) of Siemens Healthineers since December 2017. As of March 2018, the company is listed on the Frankfurt Stock Exchange as Siemens Healthineers AG (SHL). In June 2018 it entered the technology index TecDAX.
Jochen Schmitz joined Siemens in 1996 after the completion of his studies in Business Administration and Economics at the University of Augsburg. He also holds a Ph.D. in the same field. After various positions with increasing responsibility in Corporate Finance in Germany he joined Siemens Healthcare in 2004, holding several executive finance positions in the Healthcare business in the USA and Germany. Among others he was CFO of the Diagnostics Division in USA and CFO of the Imaging & Therapy Systems Division in Germany until 2011. Afterwards, he had served for six years as Corporate Vice President Controller of Siemens AG until he finally came back to Siemens Healthineers.
Michael Reitermann has been a Member of the Managing Board of Siemens Healthineers since 2015. Additionally, he is President of the Diagnostics Segment since 2018. As of March 2018, Siemens Healthineers AG (SHL) is listed on the Frankfurt Stock Exchange. In June 2018 it entered the technology index TecDAX.
Michael Reitermann has held senior leadership positions at Siemens’ healthcare business as President of the Diagnostics Division and President of the North America Region. Previously, he served in management positions with increasing responsibility in product development, marketing, sales and general management in the X-ray, Angiography and Molecular Imaging business lines. He joined Siemens in 1990 in corporate planning and became a partner at Siemens Management Consulting, before joining the healthcare business in 1998. He holds a degree in industrial engineering from the University of Karlsruhe, Germany, and an MBA from the University of British Columbia, Canada.